Genetic Signatures

57 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021 38 2020 Grant date Exercise price Balance at beginning of the year Granted during the year Converted during the year Expired/ Forfeited during the year Balance at the end of the year Number Vested and convertible at year end Options October 2016 $0.52 490,000 - (141,250) (47,500) 301,250 213,750 November 2016 $0.52 100,000 - - - 100,000 75,000 June 2017 $0.39 200,000 - (100,000) (100,000) - - October 2017 $0.34 447,500 - (37,500) (22,500) 387,500 175,000 October 2017 $0.38 250,000 - - - 250,000 125,000 August 2018 $0.53 730,000 - (32,500) (72,500) 625,000 145,000 November 2018 $0.53 200,000 - - - 200,000 50,000 February 2019 $0.84 150,000 - - - 150,000 37,500 May 2019 $1.10 200,000 - - - 200,000 50,000 November 2019 $0.98 - 945,000 - (80,000) 865,000 - March 2020 $1.13 - 200,000 - - 200,000 - Total 2,767,500 1,145,000 (311,250) (322,500) 3,278,750 871,250 Weighted average option exercise price $0.53 $1.01 $0.46 $0.58 $0.70 $0.51 Weighted average remaining contractual life of options (years) 14.28 Restricted Shares March 2015 $0.40 3,000,000 - (3,000,000) - - - April 2016 $0.49 70,000 - (70,000) - - - Total 3,070,000 - (3,070,000) - - - Weighted average option exercise price $0.40 $ - $0.40 $ - $ - $ - Weighted average remaining contractual life of options (years) - Restricted shares were offered and funded by an interest free loan from the Group at the time of listing. Restricted shares have vested and were converted to ordinary shares following repayment of the loan, which were repaid in FY20. Notes to the Financial Statements for the financial year ended 30 June 2021